Top Line: Why is increasing age associated with worse outcomes for endometrial cancer?
The Study: This study combined data from 1801 patients who participated in PORTEC-1, -2, and -3 to determine whether age is directly related to adverse outcomes or whether older patients simply have more high risk features. Interestingly, the answer was both. Older patients had a higher frequency of deep myometrial invasion (53.6% <60 v 75.3% >70), non-serous histology (9.3% <60 v 26.8% >70), and p53-mutation (6.8% <60 v 14.5% >70) as well as a lower rate of the more favorable POLEmut (18.6% <60 v 5.2% >70). But even when accounting for these differences, increasing age was still independently associated with recurrence and worse endometrial cancer-specific survival. Rates of recurrence and cancer-specific mortality increased linearly between age 50 and 80 with a hazard ratio of 1.0 typically in the vicinity of age 60. An important takeaway is that these findings were observed in a randomized clinical trial. In clinical practice, older patients are less likely to receive guideline-concordant care. This raises the possibility that in the real-world older patients may even have a third strike against them in receiving less intensive treatment by virtue of their age alone.
TBL: Among women with curable endometrial cancer, increasing age is associated with worse risk factors and also independently associated with recurrence and cancer-specific mortality. Older patients should be considered for full standard workup and treatment because of these risks. | Wakkerman, Lancet Oncol 2024
The Study: This study combined data from 1801 patients who participated in PORTEC-1, -2, and -3 to determine whether age is directly related to adverse outcomes or whether older patients simply have more high risk features. Interestingly, the answer was both. Older patients had a higher frequency of deep myometrial invasion (53.6% <60 v 75.3% >70), non-serous histology (9.3% <60 v 26.8% >70), and p53-mutation (6.8% <60 v 14.5% >70) as well as a lower rate of the more favorable POLEmut (18.6% <60 v 5.2% >70). But even when accounting for these differences, increasing age was still independently associated with recurrence and worse endometrial cancer-specific survival. Rates of recurrence and cancer-specific mortality increased linearly between age 50 and 80 with a hazard ratio of 1.0 typically in the vicinity of age 60. An important takeaway is that these findings were observed in a randomized clinical trial. In clinical practice, older patients are less likely to receive guideline-concordant care. This raises the possibility that in the real-world older patients may even have a third strike against them in receiving less intensive treatment by virtue of their age alone.
TBL: Among women with curable endometrial cancer, increasing age is associated with worse risk factors and also independently associated with recurrence and cancer-specific mortality. Older patients should be considered for full standard workup and treatment because of these risks. | Wakkerman, Lancet Oncol 2024

